Development of a vestibular schwannoma xenograft zebrafish model for in vivo antitumor drug screening

Hyun Jin Lee, Yeon Ju Yang, Sewon Jeong, Jong Dae Lee, Seok Yong Choi, Da Woon Jung, In Seok Moon

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives/Hypothesis: The development of a simple, reliable, and cost-effective animal model greatly facilitates disease treatment. We aimed to establish a rapid, simple, and reproducible live zebrafish vestibular schwannoma xenograft model for antitumor drug screening. Methods: We optimized each of the following conditions for tumor cell xenografts in zebrafish larvae: larval stage, incubation temperature, and injected cell number. We used NF2-/-mouse Schwann (SC4) cells and generated mCherry fluorescent protein-expressing cells prior to injection into zebrafish larvae. SC4 cells were counted using a fluorescence microscope, suspended in 10% fetal bovine serum, and injected into the center of the yolk sac using a microinjection system. The injected embryos were transferred to E3 medium (for zebrafish embryos), and subsequent tumor formation was observed by fluorescence microscopy over a 5-day period. To validate our model, xenografted embryos were transferred into 6-well plates (5 embryos per well) and treated with everolimus, a known antitumor drug. Results: mCherry fluorescent protein-expressing SC4 cells were successfully grafted into the yolk sacs of zebrafish embryos without any immunosuppressant treatment. At 2 days postinjection, the xenografted cells had grown into tumor masses. The optimal speed of tumor formation depended on the larval stage (30 hpf), incubation temperature (31°C), and injected cell number (200 cells). In preliminary tests, everolimus treatment yielded a > 20% reduction in the number of SC4 cells in the yolk. Conclusion: Our in vivo model has the potential to greatly facilitate vestibular schwannoma treatment because of its speed, simplicity, reproducibility, and amenability to live imaging. Level of Evidence: NA Laryngoscope, 126:E409–E415, 2016.

Original languageEnglish
Pages (from-to)E409-E415
JournalLaryngoscope
Volume126
Issue number12
DOIs
Publication statusPublished - 2016 Dec 1

Fingerprint

Preclinical Drug Evaluations
Acoustic Neuroma
Zebrafish
Heterografts
Antineoplastic Agents
Embryonic Structures
Yolk Sac
Cell Count
Larva
Neoplasms
Laryngoscopes
Temperature
Schwann Cells
Microinjections
Therapeutics
Immunosuppressive Agents
Fluorescence Microscopy
Animal Models
Fluorescence
Costs and Cost Analysis

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

Lee, Hyun Jin ; Yang, Yeon Ju ; Jeong, Sewon ; Lee, Jong Dae ; Choi, Seok Yong ; Jung, Da Woon ; Moon, In Seok. / Development of a vestibular schwannoma xenograft zebrafish model for in vivo antitumor drug screening. In: Laryngoscope. 2016 ; Vol. 126, No. 12. pp. E409-E415.
@article{e1f93c7b59c244fab8e875e75ba2af83,
title = "Development of a vestibular schwannoma xenograft zebrafish model for in vivo antitumor drug screening",
abstract = "Objectives/Hypothesis: The development of a simple, reliable, and cost-effective animal model greatly facilitates disease treatment. We aimed to establish a rapid, simple, and reproducible live zebrafish vestibular schwannoma xenograft model for antitumor drug screening. Methods: We optimized each of the following conditions for tumor cell xenografts in zebrafish larvae: larval stage, incubation temperature, and injected cell number. We used NF2-/-mouse Schwann (SC4) cells and generated mCherry fluorescent protein-expressing cells prior to injection into zebrafish larvae. SC4 cells were counted using a fluorescence microscope, suspended in 10{\%} fetal bovine serum, and injected into the center of the yolk sac using a microinjection system. The injected embryos were transferred to E3 medium (for zebrafish embryos), and subsequent tumor formation was observed by fluorescence microscopy over a 5-day period. To validate our model, xenografted embryos were transferred into 6-well plates (5 embryos per well) and treated with everolimus, a known antitumor drug. Results: mCherry fluorescent protein-expressing SC4 cells were successfully grafted into the yolk sacs of zebrafish embryos without any immunosuppressant treatment. At 2 days postinjection, the xenografted cells had grown into tumor masses. The optimal speed of tumor formation depended on the larval stage (30 hpf), incubation temperature (31°C), and injected cell number (200 cells). In preliminary tests, everolimus treatment yielded a > 20{\%} reduction in the number of SC4 cells in the yolk. Conclusion: Our in vivo model has the potential to greatly facilitate vestibular schwannoma treatment because of its speed, simplicity, reproducibility, and amenability to live imaging. Level of Evidence: NA Laryngoscope, 126:E409–E415, 2016.",
author = "Lee, {Hyun Jin} and Yang, {Yeon Ju} and Sewon Jeong and Lee, {Jong Dae} and Choi, {Seok Yong} and Jung, {Da Woon} and Moon, {In Seok}",
year = "2016",
month = "12",
day = "1",
doi = "10.1002/lary.26043",
language = "English",
volume = "126",
pages = "E409--E415",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

Development of a vestibular schwannoma xenograft zebrafish model for in vivo antitumor drug screening. / Lee, Hyun Jin; Yang, Yeon Ju; Jeong, Sewon; Lee, Jong Dae; Choi, Seok Yong; Jung, Da Woon; Moon, In Seok.

In: Laryngoscope, Vol. 126, No. 12, 01.12.2016, p. E409-E415.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of a vestibular schwannoma xenograft zebrafish model for in vivo antitumor drug screening

AU - Lee, Hyun Jin

AU - Yang, Yeon Ju

AU - Jeong, Sewon

AU - Lee, Jong Dae

AU - Choi, Seok Yong

AU - Jung, Da Woon

AU - Moon, In Seok

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Objectives/Hypothesis: The development of a simple, reliable, and cost-effective animal model greatly facilitates disease treatment. We aimed to establish a rapid, simple, and reproducible live zebrafish vestibular schwannoma xenograft model for antitumor drug screening. Methods: We optimized each of the following conditions for tumor cell xenografts in zebrafish larvae: larval stage, incubation temperature, and injected cell number. We used NF2-/-mouse Schwann (SC4) cells and generated mCherry fluorescent protein-expressing cells prior to injection into zebrafish larvae. SC4 cells were counted using a fluorescence microscope, suspended in 10% fetal bovine serum, and injected into the center of the yolk sac using a microinjection system. The injected embryos were transferred to E3 medium (for zebrafish embryos), and subsequent tumor formation was observed by fluorescence microscopy over a 5-day period. To validate our model, xenografted embryos were transferred into 6-well plates (5 embryos per well) and treated with everolimus, a known antitumor drug. Results: mCherry fluorescent protein-expressing SC4 cells were successfully grafted into the yolk sacs of zebrafish embryos without any immunosuppressant treatment. At 2 days postinjection, the xenografted cells had grown into tumor masses. The optimal speed of tumor formation depended on the larval stage (30 hpf), incubation temperature (31°C), and injected cell number (200 cells). In preliminary tests, everolimus treatment yielded a > 20% reduction in the number of SC4 cells in the yolk. Conclusion: Our in vivo model has the potential to greatly facilitate vestibular schwannoma treatment because of its speed, simplicity, reproducibility, and amenability to live imaging. Level of Evidence: NA Laryngoscope, 126:E409–E415, 2016.

AB - Objectives/Hypothesis: The development of a simple, reliable, and cost-effective animal model greatly facilitates disease treatment. We aimed to establish a rapid, simple, and reproducible live zebrafish vestibular schwannoma xenograft model for antitumor drug screening. Methods: We optimized each of the following conditions for tumor cell xenografts in zebrafish larvae: larval stage, incubation temperature, and injected cell number. We used NF2-/-mouse Schwann (SC4) cells and generated mCherry fluorescent protein-expressing cells prior to injection into zebrafish larvae. SC4 cells were counted using a fluorescence microscope, suspended in 10% fetal bovine serum, and injected into the center of the yolk sac using a microinjection system. The injected embryos were transferred to E3 medium (for zebrafish embryos), and subsequent tumor formation was observed by fluorescence microscopy over a 5-day period. To validate our model, xenografted embryos were transferred into 6-well plates (5 embryos per well) and treated with everolimus, a known antitumor drug. Results: mCherry fluorescent protein-expressing SC4 cells were successfully grafted into the yolk sacs of zebrafish embryos without any immunosuppressant treatment. At 2 days postinjection, the xenografted cells had grown into tumor masses. The optimal speed of tumor formation depended on the larval stage (30 hpf), incubation temperature (31°C), and injected cell number (200 cells). In preliminary tests, everolimus treatment yielded a > 20% reduction in the number of SC4 cells in the yolk. Conclusion: Our in vivo model has the potential to greatly facilitate vestibular schwannoma treatment because of its speed, simplicity, reproducibility, and amenability to live imaging. Level of Evidence: NA Laryngoscope, 126:E409–E415, 2016.

UR - http://www.scopus.com/inward/record.url?scp=84971524613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971524613&partnerID=8YFLogxK

U2 - 10.1002/lary.26043

DO - 10.1002/lary.26043

M3 - Article

C2 - 27242319

AN - SCOPUS:84971524613

VL - 126

SP - E409-E415

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 12

ER -